GLP-2TZ is a synthetic dual incretin agonist supplied by Kylo Peptides as a lyophilized research peptide. It is a 39-residue, fatty-acid-modified molecule that activates both the GIP receptor and the GLP-1 receptor, which makes it a standard tool for researchers studying how the two incretin pathways interact. This overview covers the product's specifications, how it signals, how to design experiments around it, and what to verify on the certificate before use. The full listing is on the GLP-2TZ product page. All material discussed here is for laboratory research use only.
Kylo supplies GLP-2TZ in 10 mg and 30 mg vials as a sterile lyophilized powder with an acetate counterion. Each vial is nitrogen-flushed, sealed with a tamper-evident closure, and carries the lot ID printed on the label. The lot ID ties the vial to its published certificate.
Compound: GLP-2 (TZ), synthetic dual incretin agonist
Length: 39 amino acids
Molecular formula: C225H348N48O68
Average mass: ~4,813.45 g/mol
CAS number: 2023788-19-2
Receptor targets: GIPR and GLP-1R
Form: Lyophilized powder, acetate counterion
Vial sizes: 10 mg, 30 mg
Storage: −20 °C, sealed and protected from light
Use: Research use only
Kylo lists purity at ≥99% by HPLC, with identity confirmed by LC-MS against the reference mass. Confirm the exact purity figure on the certificate for your lot. You can see the full specification table on the GLP-2TZ product page.
The peptide is built mainly on the native GIP sequence, with two non-coded α-aminoisobutyric acid (Aib) residues at positions 2 and 13, a C-terminal amide, and a C20 fatty diacid attached to Lys20 through a γGlu-2×OEG linker.
Each modification has a job. Aib at position 2 blocks DPP-4 cleavage, the main route that destroys native incretins within minutes. The fatty diacid binds albumin, which extends exposure well beyond what an unmodified peptide delivers. The backbone residues keep high-affinity contact with both receptors.
For the bench, this means GLP-2TZ is a stable, long-acting agonist. You can study sustained receptor engagement over hours or days rather than a short pulse.
GIPR and GLP-1R are class B GPCRs that signal mainly through Gs and cAMP. GLP-2TZ engages both, but not equally.
At GIPR, the molecule behaves much like native GIP. Structural studies show that core-contact residues let it carry the fatty acid modification while keeping GIP-level affinity. At GLP-1R, published work describes a bias toward cAMP signaling over β-arrestin recruitment, along with reduced receptor internalization compared with native GLP-1.
Reported affinity values differ across studies, assay formats, and albumin conditions. If your question depends on relative potency at the two receptors, measure it in your own system rather than borrowing a number.
Whether signaling bias, dual engagement, or potency drives a given in vivo phenotype is still being worked out. Design your experiments to separate those variables.
Albumin binding is built into the molecule, and it changes how GLP-2TZ behaves on the bench.
Serum shifts potency. In media containing serum or BSA, much of the peptide is bound and unavailable to the receptor. Apparent EC50 values shift right, sometimes substantially. Compare potency only between conditions with matched albumin content, and report that content.
Plastic adsorption is a real loss. Lipidated peptides stick to polypropylene and polystyrene, especially at low concentration in protein-free buffer. Use low-binding tubes and tips. Add a carrier protein where the assay allows. Check recovery on any serial dilution made in plain buffer.
Exposure differs by species. Rodent pharmacokinetics run faster than those in larger animals. Measure exposure in your own model rather than assuming it.
Published work with this class of molecule falls into a few areas:
Incretin receptor pharmacology. cAMP, β-arrestin, and internalization assays at GIPR and GLP-1R, including signaling bias studies.
Metabolic models. Diet-induced obese rodents, with readouts such as food intake, body weight, glucose tolerance, and insulin secretion.
Tissue-level mechanism. Receptor expression and signaling in pancreas, adipose tissue, and discrete brain regions.
Comparator work. Benchmarking against GLP-1-selective agonists, or against triple agonists, to isolate what GIPR engagement contributes.
Peptide chemistry and analytics. Lipidated peptide synthesis, stability, and characterization.
If your work sits alongside other metabolic or signaling targets, the Kylo research peptide catalog lists related compounds with the same documentation standard.
Controls decide whether a dual-agonist result means anything.
Minimum control set:
Vehicle matched for buffer, counterion, and albumin content
Native GIP(1-42) and GLP-1(7-36) as single-receptor references
A GLP-1-selective lipidated agonist to isolate the GIPR contribution
Receptor-null cells or an antagonist to confirm the signal runs through the receptor you think it does
Cell systems. HEK293 or CHO cells expressing recombinant human GIPR or GLP-1R work well, with cAMP as the primary readout and β-arrestin recruitment if bias is the question. Cells expressing both receptors reveal crosstalk but make attribution harder.
Species. Receptor pharmacology doesn't transfer cleanly between rodent and human orthologs. Name the species in every figure legend.
Dose selection. Take ranges from peer-reviewed work in your specific model rather than from vendor data sheets.
Kylo states that it tests every batch on seven assays before release and publishes the results on the certificate before the lot opens for sale:
Sterility (USP <71>)
Endotoxin (USP <85>)
Purity by HPLC-UV
Identity by LC-MS
Heavy metals by ICP-MS
Net peptide content
Batch consistency
For a lipidated peptide, three of these matter most. LC-MS identity confirms the intact mass and shows the fatty diacid is present, since a missing acylation shifts the mass. Net content tells you how much peptide is in the vial, which sets the accuracy of every concentration you make. Endotoxin screening protects in vivo and primary cell work.
Read the details on Kylo's quality standards and testing methodology pages, and browse published certificates in the COA library.
Whichever lot you receive, run this check before the first experiment:
Lot ID. It must match the number printed on your vial.
Observed mass. It should sit near 4813 Da. Ask for the spectrum itself, not only a "confirmed" line.
Chromatogram. Look at the column, gradient, and wavelength, and check for shoulder peaks. Hydrophobic lipidated peptides can aggregate on reversed-phase columns, so one method is a starting point.
Net peptide content. Use it to correct molar calculations. Gross weight overstates the peptide in the vial.
Counterion. The acetate form avoids the TFA effects that can interfere with cell assays. Keep your vehicle control matched.
Endotoxin. Required for any in vivo or primary cell use.
Kylo also states that it backs the certificate with a guarantee. A vial that doesn't match its published certificate is replaced or refunded within 30 days of delivery. See the shipping and returns policy for the terms.
Kylo supplies handling guidance with the product, and it lines up with standard practice for lipidated peptides:
Keep lyophilized vials at −20 °C, sealed and away from light.
Let the vial reach room temperature before opening to prevent condensation.
Add liquid gently down the inside wall of the vial. Swirl rather than shake, since lipidated peptides can foam and aggregate.
Hold reconstituted material at 2–8 °C for short periods only.
Aliquot into single-use volumes and avoid repeated freeze-thaw cycles.
Use low-binding tubes and tips throughout.
If your experiment runs for weeks, verify stability under your own conditions by HPLC.
Kylo dispatches orders within 24 hours on business days with tracking, typically arriving in 2 to 4 business days. Shipping is within the United States only. Orders above $150 ship free, and a cold pack is available as an add-on. International researchers should check the shipping policy before ordering.
GLP-2TZ is supplied for laboratory research use only and is not intended for human or veterinary use. The practical limits sit in the assay: albumin-dependent potency, plastic adsorption, species differences in receptor pharmacology, and the open question of how much each receptor contributes to a given in vivo phenotype. Plan for them before the first experiment.
What is GLP-2TZ?
A synthetic, fatty-acid-modified dual GIP/GLP-1 receptor agonist, 39 amino acids long, supplied by Kylo as a lyophilized research peptide.
What mass should the COA show?
About 4813 Da for the intact peptide, with CAS 2023788-19-2. Compare it against the product page and your lot certificate.
Which vial sizes are available?
10 mg and 30 mg.
How should it be stored?
Lyophilized at −20 °C, sealed and protected from light. Once reconstituted, keep it at 2–8 °C and avoid repeated freeze-thaw cycles.
Why does my EC50 change between experiments?
Check albumin content in the media first, then peptide adsorption to plastic, then net peptide content. These three account for most variability.
Which cell lines should I use?
HEK293 or CHO cells expressing recombinant human GIPR or GLP-1R, with cAMP as the primary readout.
Where can I find lot documentation?
In the Kylo COA library or by checking the lot ID on your vial against the product page. Questions go through the FAQ.
GLP-2TZ gives researchers a stable, long-acting dual incretin agonist for studying GIP and GLP-1 receptor signaling together. Get the most from it by accounting for albumin in your assays, correcting for net peptide content, using single-receptor comparators, and matching the lot certificate to your vial before the first experiment.
Ready to review the specifications? Open the GLP-2TZ product page and check the lot documentation against your vial.